Advertisement

ADVERTISEMENT

Diffuse Large B-Cell Lymphoma

Conference Insider
Long-Lasting Remission With Dual Targeting CAR-T Therapy for R/R DLBCL
12/15/2020
Patients with relapsed/refractory DLBCL given AUTO3 (a CD19/22 dual targeting CAR-T therapy) plus pembrolizumab had durable responses.
Patients with relapsed/refractory DLBCL given AUTO3 (a CD19/22 dual targeting CAR-T therapy) plus pembrolizumab had durable responses.
Patients with...
12/15/2020
Oncology
Conference Insider
Avelumab Plus R-CHOP Effective for Newly Diagnosed DLBCL
12/10/2020
Avelumab plus R-CHOP yielded high rates of complete response with manageable toxicity in a cohort of patients with newly diagnosed DLBCL.
Avelumab plus R-CHOP yielded high rates of complete response with manageable toxicity in a cohort of patients with newly diagnosed DLBCL.
Avelumab plus R-CHOP yielded...
12/10/2020
Oncology
Conference Insider
Mosunetuzumab Safe, Effective for Elderly Patients With DLBCL
12/07/2020
Single-agent mosunetuzumab shows efficacy, remarkable safety, as a chemo-free option for previously untreated elderly/unfit patients with DLBCL.
Single-agent mosunetuzumab shows efficacy, remarkable safety, as a chemo-free option for previously untreated elderly/unfit patients with DLBCL.
Single-agent mosunetuzumab shows...
12/07/2020
Oncology
medical
Conference Insider
Polatuzumab Vedotin Plus Venetoclax, Rituximab Shows Promise in R/R DLBCL
12/03/2020
Polatuzumab vedotin plus venetoclax with rituximab shows promise in the treatment of patients with R/R DLBCL, according to phase 1b/2 study findings.
Polatuzumab vedotin plus venetoclax with rituximab shows promise in the treatment of patients with R/R DLBCL, according to phase 1b/2 study findings.
Polatuzumab vedotin plus...
12/03/2020
Oncology
sh
Conference Insider
Frailty Tied to Increased 1-Year Mortality in Patients with Newly Diagnosed DLBCL
12/02/2020
According to data being presented at the virtual ASH Annual Meeting and Exposition, fragility in patients with DLBCL is significantly associated with 1-year mortality.
According to data being presented at the virtual ASH Annual Meeting and Exposition, fragility in patients with DLBCL is significantly associated with 1-year mortality.
According to data being...
12/02/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD logo
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use